Oppenheimer
The Next Wave of Healthy Aging
May 26, 2026
Key Takeaways:
- The focus is shifting from longevity to healthy aging. The goal is not simply to live longer, but to spend more years healthy, functional, and independent.
- The health span gap is a measurable challenge. People are living longer, but many spend a meaningful portion of those extra years managing disease, disability, or cognitive decline.
- Obesity drugs may serve as a gateway to healthy aging. GLP-1-based treatments have opened the door to broader conversations about prevention, metabolic health, and diseases of aging.
- The next wave of innovation may focus on maintenance, muscle preservation, and inflammation. Current weight-loss therapies are powerful, but challenges remain around discontinuation, weight regain, lean mass loss, and long-term use.
- Personalized preventive medicine could define the next decade. Earlier detection, better diagnostics, and more targeted therapies may help identify the right intervention for the right patient before disease progresses.
In this episode of Let’s Talk Future, Jane Ross speaks with Jay Olson, CFA, Managing Director and Senior Analyst covering Biotechnology at Oppenheimer, about healthy aging and the biotech innovation shaping the field.
Rather than focusing on living longer, Jay emphasizes health span: the years people spend healthy, active, and functional. He explains that obesity is closely linked to many diseases of aging, making obesity drugs an important part of the healthy aging conversation.
The discussion also looks at what comes next for GLP-1-based therapies, including long-term weight maintenance, muscle preservation, reduced inflammation, and more personalized treatment. Jay also highlights the importance of prevention, early detection, and simple lifestyle factors such as social connection and hearing health.
The takeaway: healthy aging is becoming a broader healthcare and investment theme, with obesity, diagnostics, inflammation, and preventive medicine at the center.
Up Next
Disclosure
This podcast is the property of Oppenheimer & Co. Inc. and should not be copied, distributed, published or reproduced, in whole or in part. The information/commentary contained in this recording was obtained from market conditions and professional sources, and is educational in nature. The information presented has been derived from sources believed to be reliable but is not guaranteed as to accuracy and does not purport to be a complete analysis of any strategy, plan, security, company, or industry involved. Opinions expressed herein are subject to change without notice. Oppenheimer has no obligation to provide any updates or changes. Any examples used in this material are generic, hypothetical and for illustration purposes only. All price references and market forecasts are as of the date of recording. This podcast is not a product of Oppenheimer Research, nor does it provide any financial, economic, legal, accounting, or tax advice or recommendations. Any liability therefore (including in respect of direct, indirect or consequential loss or damage) is expressly disclaimed.
Securities and other financial instruments that may be discussed in this report or recommended or sold are not insured by the Federal Deposit Insurance Corporation and are not deposits or obligations of any insured depository institution. Investments involve numerous risks including market risk, counterparty default risk and liquidity risk. Securities and other financial investments at times maybe difficult to value or sell. The value of financial instruments may fluctuate, and investors may lose their entire principal investment. Prior to making any investment or financial decisions, an investor should seek advice from their personal financial, legal, tax and other professional advisors that take into account all of the particular facts and circumstances of an investor's own situation. The views and strategies described may not be suitable for all investors. This report does not take into account the investment objectives, financial situation or specific needs of any particular client of Oppenheimer or its affiliates.
This podcast may contain forward looking statements or projections regarding future events. Forward-looking statements and projections are based on the opinions and estimates of Oppenheimer as of the date of this podcast, and are subject to a variety of risks and uncertainties as well as other factors, including economic, political, and public health factors, that could cause actual events or results to differ materially from those anticipated in the forward-looking statements and projections.
The performance of a benchmark index is not indicative of the performance of any particular investment; however, they are considered representative of their respective market segments. Please note that indexes are unmanaged and their returns do not take into account any of the costs associated with buying and selling individual securities. Individuals cannot invest directly in an index.
This content is intended for informational purposes only and should not be construed as investment advice or a recommendation to buy or sell any security. No part of this podcast should be interpreted as a testimonial regarding the advisory services of Oppenheimer & Co. Inc. Any references to performance, investment opportunities, or market outlooks are based on current opinions, which are subject to change without notice. Past performance is not indicative of future results. All investments involve risk, including the potential loss of principal.
Oppenheimer Transacts Business on all Principal US Exchanges and is a Member of SIPC. 8942277.1